NEOGENOMICS INC — Director's Dealing 2019

Mar 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2019-03-01

Reporting Person: SHOVLIN ROBERT J. (President, Clinical Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-01	Common Stock	A	10944	—	Acquired	148321	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-01	Stock Option (Right to Buy)	$19.6	A	66897	Acquired	2024-03-01	Common Stock (66897.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (288500.0)	288500	Direct
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (133334.0)	133334	Direct
Stock Option (Right to Buy)	$7.15	2021-04-20	Common Stock (66666.0)	66666	Direct

Footnotes

F1: On March 1, 2019, Mr. Shovlin was granted an option to purchase 66,897 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.

F2: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F3: On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F4: On April 20, 2016, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.